Stockscreener 앱 받기
68.57
1.54%
-1.07
시간 외 거래:
68.57
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Halozyme (HALO) CLO reports RSU vesting and share withholding for taxes - Stock Titan
(HALO) Volatility Zones as Tactical Triggers - Stock Traders Daily
Halozyme Therapeutics Expects Proposed Rule to Have Little Impact on Royalties - marketscreener.com
Halozyme sees minimal impact from Medicare drug pricing rule - Investing.com
Halozyme sees minimal impact from Medicare drug pricing rule By Investing.com - Investing.com UK
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 - PR Newswire
HALOZYME THERAPEUTICS INC (HALO) Stock Chart - ChartMill
Halozyme Therapeutics (HALO) up 0.8% since last earnings report: Can it continue? - MSN
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance Singapore
Halozyme Therapeutics (HALO) CFO files Form 3 insider ownership statement - Stock Titan
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Uncovering a 17.29% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Natixis Advisors LLC Has $6.68 Million Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Quick ratio of Halozyme Therapeutics, Inc. – XETR:RV7 - TradingView
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics, Inc. Income Statement – XETR:RV7 - TradingView
TD Asset Management Inc Lowers Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme licenses Hypercon technology to Oruka for psoriasis drug - Investing.com
Halozyme Therapeutics (HALO) Gains 2.76% as Shares Approach Key ResistanceMA Crossover - newsline.com
How New ENHANZE Data And Analyst Support At Halozyme Therapeutics (HALO) Has Changed Its Investment Story - Yahoo Finance
Halozyme Therapeutics(HALO.US) Officer Sells US$3.37 Million in Common Stock - Moomoo
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options By Investing.com - Investing.com South Africa
Halozyme Therapeutics Stock Gains 5.2% on Analyst Buy Rating and argenx Data NewsNews and Statistics - IndexBox
Halozyme CEO Helen Torley sells $3.37m in shares after exercising options - Investing.com
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today - Yahoo Finance
Halozyme (NASDAQ: HALO) CEO sells 50K shares after exercising 50K options - Stock Titan
Halozyme Therapeutics (NASDAQ:HALO) Trading Up 5.6%Here's What Happened - MarketBeat
Halozyme Therapeutics Jumps 5.4% Amid Sector-Wide Rally - AlphaStreet
Benchmark reiterates Halozyme stock Buy rating on long-term potential - Investing.com
Benchmark reiterates Halozyme stock Buy rating on long-term potential By Investing.com - Investing.com Canada
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E - ChartMill
Insider Sell Alert: Bernadette Connaughton Sells Shares of Haloz - GuruFocus
Insider Sell Alert: Bernadette Connaughton Sells Shares of Halozyme Therapeutics Inc (HALO) - GuruFocus
Director at Halozyme (NASDAQ: HALO) sells shares under Rule 10b5-1 plan - Stock Titan
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a 26% Potential Upside for Investors - DirectorsTalk Interviews
Legal & General Group Plc Cuts Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme earnings up next: Can drug delivery platform sustain growth? By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (HALO) Holds Above Key Support as Selling Pressure EasesInstitutional Buy Signals - newsline.com
Halozyme to acquire Elektrofi, a biopharma focused on drug delivery - MSN
Halozyme Therapeutics Inc at Leerink Global Healthcare Conference Transcript - GuruFocus
Implied volatility surging for Halozyme Therapeutics stock options - MSN
Halozyme Therapeutics Q1 earnings call highlights - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - Yahoo Finance
Assessing Halozyme Therapeutics (HALO) Valuation After Mixed Short Term And Strong Multi Year Share Returns - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Unveiling a Promising 22.8% Potential Upside - DirectorsTalk Interviews
(HALO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
LSV Asset Management Has $87.56 Million Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Mizuho Markets Americas LLC Acquires 926,526 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
HALO News | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns - Sahm
New GSK ENHANZE Deal and Bigger Buybacks Might Change The Case For Investing In Halozyme (HALO) - simplywall.st
Halozyme posts strong Q1 earnings, boosts share buyback with $1B program amid robust royalty growth - Pluang
Halozyme Therapeutics: Royalty King (NASDAQ:HALO) - Seeking Alpha
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Alteogen Gains Momentum in Patent Defense for Merck's Subcutaneous Keytruda - thelec.net
Halozyme Therapeutics (HALO) Stock Analysis: A 27.3% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Halozyme Therapeutics Experiences Valuation Adjustment Amid Competitive Biotechnology Landscape - Markets Mojo
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
2.60%
0.94%
자본화:
|
볼륨(24시간):